Regeneron Pharmaceuticals, Inc. (REGN)
- Previous Close
968.00 - Open
970.00 - Bid 972.41 x 100
- Ask 973.87 x 100
- Day's Range
966.85 - 979.98 - 52 Week Range
684.81 - 998.33 - Volume
351,356 - Avg. Volume
455,508 - Market Cap (intraday)
107.299B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
28.73 - EPS (TTM)
33.89 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,053.60
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
www.regeneron.comRecent News: REGN
Performance Overview: REGN
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REGN
Valuation Measures
Market Cap
107.30B
Enterprise Value
99.48B
Trailing P/E
28.75
Forward P/E
22.12
PEG Ratio (5yr expected)
1.60
Price/Sales (ttm)
8.47
Price/Book (mrq)
3.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
29.45%
Return on Assets (ttm)
7.74%
Return on Equity (ttm)
15.28%
Revenue (ttm)
13.1B
Net Income Avi to Common (ttm)
3.86B
Diluted EPS (ttm)
33.89
Balance Sheet and Cash Flow
Total Cash (mrq)
10.52B
Total Debt/Equity (mrq)
10.02%
Levered Free Cash Flow (ttm)
3.03B
Research Analysis: REGN
Company Insights: REGN
REGN does not have Company Insights